drugset / Trial / NCT04875611
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Phase 2
Recruiting
32 enrolled
Maria Sklodowska-Curie National Research Institute of Oncology
KCRI · collab
NaSingle-groupOpen-labelTreatment
Summary
Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.
Timeline
- Start
- 2021-08-26
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |